Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

FDA lifts clinical hold enabling resumption of clinical trials FDA has granted a Type A Meeting to discuss path forward for BLA Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging